Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ardea Biosciences, Inc.    RDEA

SummaryNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

Ardea Biosciences, Inc. : Board of Directors Under Investigation for Potential Breaches of Fiduciary Duty by Law Offices of Howard G. Smith

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 05:10pm CEST

Law Offices of Howard G. Smith announces that it is investigating potential claims against the Board of Directors of Ardea Biosciences, Inc. ("Ardea" or the "Company") (NASDAQ: RDEA) related to the proposed acquisition of the Company by AstraZeneca. The transaction is valued at approximately $1.26 billion or $32 per share.

This investigation concerns whether the Board of Directors of Ardea breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. The Company has seen substantial recent growth. Further, at least one analyst has set a target price for the Company's stock at $40.00 per share.

If you are a shareholder of Ardea, if you have information or would like to learn more about our investigation, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
(215) 638-4847
Toll Free, (888) 638-4847
howardsmith@howardsmithlaw.com
http://www.howardsmithlaw.com


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARDEA BIOSCIENCES, INC.
2012 AstraZeneca hungry to refill medicine cabinet
2012DJAstraZeneca Completes Acquisition of Ardea Biosciences
2012 GSK goes hostile with $2.6 billion Human Genome offer
2012 Biotech targets fight back as Big Pharma circles
2012 ARDEA BIOSCIENCES, INC. : Securities Lawyers at Goldfarb LLP Seeking More Money,..
2012 Warner Chilcott to explore sale of company
2012 ARDEA BIOSCIENCES, INC. : Law Office of Brodsky & Smith, LLC Announces Investiga..
2012DJPharma M&A Surge Spurred By Necessity And Opportunity
2012 AstraZeneca CEO quits as drug sales tumble
2012 Watson to buy Actavis for at least $5.6 billion
More news
Sector news : Bio Therapeutic Drugs
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
More sector news : Bio Therapeutic Drugs
Advertisement
Income Statement Evolution
More Financials
Sector and Competitors
1st jan.Capitalization (M$)
ARDEA BIOSCIENCES, INC..0
AMGEN, INC.7.68%130 813
GILEAD SCIENCES, INC.-19.59%107 381
CELGENE CORPORATION-8.63%84 821
REGENERON PHARMACEUTIC..-24.40%43 212
VERTEX PHARMACEUTICALS..-27.97%22 456
More Results